Has Stephen Smith, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,380 in general payments to Stephen Smith, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Smith, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Smith, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Smith, MD

Retina Specialist · Stanford, CANPI 1013278118

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,035 of the $1,380 with a category attached, or 75.0%. Bausch & Lomb Americas Inc. accounts for 75.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $1,035 and has fallen 98.3% since, to $18 in 2025. That places this record below the midpoint for retina specialist clinicians in CA, where the typical reported total is $3,667.

$1,380in general payments, 2019–2025

Across 6 payments — averaging $229.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bausch & Lomb Americas Inc.$1K
Astellas Pharma US Inc$149
Alimera Sciences, Inc.$125
Tarsus Pharmaceuticals, Inc.$71

What the payments were for

Speaking & faculty fees$1,03575%
Food & beverage$34525%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bausch & Lomb Americas Inc.	1	$1,035
Astellas Pharma US Inc	1	$149
Alimera Sciences, Inc.	1	$125
Tarsus Pharmaceuticals, Inc.	3	$71

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,380 in reported general payments places this provider in the 25th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California →

Medicare billing

Part B allowed, 2024

$895,633

Medicare patients

1,476

Services billed

11,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	53	$2,946
Ketorolac Tromethamine	25	$741
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	26	$176

Paid to pharmacies, not to this prescriber.

Other retina specialist in Stanford

Ehsan RahimyStanford$1.5M
Diana DoStanford$318K
Theodore LengStanford$223K
Charles DeboerStanford$79K
Prithvi MruthyunjayaStanford$74K
Mary HartnettStanford$73K
Dilsher DhootSanta Barbara$1.9M
Darius MoshfeghiPalo Alto$1.4M
Nathan SteinleSanta Barbara$1.1M
Roger GoldbergWalnut Creek$1.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →